Cargando…

Allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: systems biology study

BACKGROUND: Myocardial microvascular loss after myocardial infarction (MI) remains a therapeutic challenge. Autologous stem cell therapy was considered as an alternative; however, it has shown modest benefits due to the impairing effects of cardiovascular risk factors on stem cells. Allogenic adipos...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilahur, Gemma, Oñate, Blanca, Cubedo, Judit, Béjar, Maria Teresa, Arderiu, Gemma, Peña, Esther, Casaní, Laura, Gutiérrez, Manuel, Capdevila, Antoni, Pons-Lladó, Guillem, Carreras, Francesc, Hidalgo, Alberto, Badimon, Lina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345145/
https://www.ncbi.nlm.nih.gov/pubmed/28279225
http://dx.doi.org/10.1186/s13287-017-0509-2
_version_ 1782513659561377792
author Vilahur, Gemma
Oñate, Blanca
Cubedo, Judit
Béjar, Maria Teresa
Arderiu, Gemma
Peña, Esther
Casaní, Laura
Gutiérrez, Manuel
Capdevila, Antoni
Pons-Lladó, Guillem
Carreras, Francesc
Hidalgo, Alberto
Badimon, Lina
author_facet Vilahur, Gemma
Oñate, Blanca
Cubedo, Judit
Béjar, Maria Teresa
Arderiu, Gemma
Peña, Esther
Casaní, Laura
Gutiérrez, Manuel
Capdevila, Antoni
Pons-Lladó, Guillem
Carreras, Francesc
Hidalgo, Alberto
Badimon, Lina
author_sort Vilahur, Gemma
collection PubMed
description BACKGROUND: Myocardial microvascular loss after myocardial infarction (MI) remains a therapeutic challenge. Autologous stem cell therapy was considered as an alternative; however, it has shown modest benefits due to the impairing effects of cardiovascular risk factors on stem cells. Allogenic adipose-derived stem cells (ASCs) may overcome such limitations, and because of their low immunogenicity and paracrine potential may be good candidates for cell therapy. In the present study we investigated the effects of allogenic ASCs and their released products on cardiac rarefaction post MI. METHODS: Pig subcutaneous adipose tissue ASCs were isolated, expanded and GFP-labeled. ASC angiogenic function was assessed by the in-vivo chick chorioallantoic membrane (CAM) model. Pigs underwent MI induction and 7 days after were randomized to receive: allogenic ASCs (intracoronary infusion); conditioned media (CM; intravenous infusion); ASCs + CM; or PBS/placebo (control). Cardiac damage and function were monitored by 3-T cardiac magnetic resonance imaging upon infusion (baseline CMR) and 1 and 3 weeks thereafter. We assessed in the myocardium: microvessel density; angiogenic markers (CD105, CD31, TF, VEGFR2, VEGFR1, vWF, eNOS, CD62); collagen deposition; and reparative fibrosis (TGFβ/TβRII/collagen). Differential proteomics of ASCs and CM was performed to characterize the ASC protein signature. RESULTS: CAM indicated a significant ASC proangiogenic capacity. In pigs after MI, only PBS/placebo animals displayed an impaired cardiac function 3 weeks after infusion (p < 0.05 vs baseline). Administration of ASCs + CM significantly enhanced neovessel formation and favored cardiac repair post MI (p < 0.05 vs the other groups). Molecular markers of angiogenesis were significantly upregulated both at transcriptional and protein levels (p < 0.05). The in-silico bioinformatics analysis of the ASC and CM proteome (interactome) indicated activation of a coordinated protein network involved in the formation of microvessels and the resolution of rarefaction. CONCLUSION: Coadministration of allogenic ASCs and their CM synergistically contribute to the neovascularization of the infarcted myocardium through a coordinated upregulation of the proangiogenic protein interactome. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13287-017-0509-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5345145
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53451452017-03-14 Allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: systems biology study Vilahur, Gemma Oñate, Blanca Cubedo, Judit Béjar, Maria Teresa Arderiu, Gemma Peña, Esther Casaní, Laura Gutiérrez, Manuel Capdevila, Antoni Pons-Lladó, Guillem Carreras, Francesc Hidalgo, Alberto Badimon, Lina Stem Cell Res Ther Research BACKGROUND: Myocardial microvascular loss after myocardial infarction (MI) remains a therapeutic challenge. Autologous stem cell therapy was considered as an alternative; however, it has shown modest benefits due to the impairing effects of cardiovascular risk factors on stem cells. Allogenic adipose-derived stem cells (ASCs) may overcome such limitations, and because of their low immunogenicity and paracrine potential may be good candidates for cell therapy. In the present study we investigated the effects of allogenic ASCs and their released products on cardiac rarefaction post MI. METHODS: Pig subcutaneous adipose tissue ASCs were isolated, expanded and GFP-labeled. ASC angiogenic function was assessed by the in-vivo chick chorioallantoic membrane (CAM) model. Pigs underwent MI induction and 7 days after were randomized to receive: allogenic ASCs (intracoronary infusion); conditioned media (CM; intravenous infusion); ASCs + CM; or PBS/placebo (control). Cardiac damage and function were monitored by 3-T cardiac magnetic resonance imaging upon infusion (baseline CMR) and 1 and 3 weeks thereafter. We assessed in the myocardium: microvessel density; angiogenic markers (CD105, CD31, TF, VEGFR2, VEGFR1, vWF, eNOS, CD62); collagen deposition; and reparative fibrosis (TGFβ/TβRII/collagen). Differential proteomics of ASCs and CM was performed to characterize the ASC protein signature. RESULTS: CAM indicated a significant ASC proangiogenic capacity. In pigs after MI, only PBS/placebo animals displayed an impaired cardiac function 3 weeks after infusion (p < 0.05 vs baseline). Administration of ASCs + CM significantly enhanced neovessel formation and favored cardiac repair post MI (p < 0.05 vs the other groups). Molecular markers of angiogenesis were significantly upregulated both at transcriptional and protein levels (p < 0.05). The in-silico bioinformatics analysis of the ASC and CM proteome (interactome) indicated activation of a coordinated protein network involved in the formation of microvessels and the resolution of rarefaction. CONCLUSION: Coadministration of allogenic ASCs and their CM synergistically contribute to the neovascularization of the infarcted myocardium through a coordinated upregulation of the proangiogenic protein interactome. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13287-017-0509-2) contains supplementary material, which is available to authorized users. BioMed Central 2017-03-09 /pmc/articles/PMC5345145/ /pubmed/28279225 http://dx.doi.org/10.1186/s13287-017-0509-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Vilahur, Gemma
Oñate, Blanca
Cubedo, Judit
Béjar, Maria Teresa
Arderiu, Gemma
Peña, Esther
Casaní, Laura
Gutiérrez, Manuel
Capdevila, Antoni
Pons-Lladó, Guillem
Carreras, Francesc
Hidalgo, Alberto
Badimon, Lina
Allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: systems biology study
title Allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: systems biology study
title_full Allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: systems biology study
title_fullStr Allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: systems biology study
title_full_unstemmed Allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: systems biology study
title_short Allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: systems biology study
title_sort allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: systems biology study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345145/
https://www.ncbi.nlm.nih.gov/pubmed/28279225
http://dx.doi.org/10.1186/s13287-017-0509-2
work_keys_str_mv AT vilahurgemma allogenicadiposederivedstemcelltherapyovercomesischemiainducedmicrovesselrarefactioninthemyocardiumsystemsbiologystudy
AT onateblanca allogenicadiposederivedstemcelltherapyovercomesischemiainducedmicrovesselrarefactioninthemyocardiumsystemsbiologystudy
AT cubedojudit allogenicadiposederivedstemcelltherapyovercomesischemiainducedmicrovesselrarefactioninthemyocardiumsystemsbiologystudy
AT bejarmariateresa allogenicadiposederivedstemcelltherapyovercomesischemiainducedmicrovesselrarefactioninthemyocardiumsystemsbiologystudy
AT arderiugemma allogenicadiposederivedstemcelltherapyovercomesischemiainducedmicrovesselrarefactioninthemyocardiumsystemsbiologystudy
AT penaesther allogenicadiposederivedstemcelltherapyovercomesischemiainducedmicrovesselrarefactioninthemyocardiumsystemsbiologystudy
AT casanilaura allogenicadiposederivedstemcelltherapyovercomesischemiainducedmicrovesselrarefactioninthemyocardiumsystemsbiologystudy
AT gutierrezmanuel allogenicadiposederivedstemcelltherapyovercomesischemiainducedmicrovesselrarefactioninthemyocardiumsystemsbiologystudy
AT capdevilaantoni allogenicadiposederivedstemcelltherapyovercomesischemiainducedmicrovesselrarefactioninthemyocardiumsystemsbiologystudy
AT ponslladoguillem allogenicadiposederivedstemcelltherapyovercomesischemiainducedmicrovesselrarefactioninthemyocardiumsystemsbiologystudy
AT carrerasfrancesc allogenicadiposederivedstemcelltherapyovercomesischemiainducedmicrovesselrarefactioninthemyocardiumsystemsbiologystudy
AT hidalgoalberto allogenicadiposederivedstemcelltherapyovercomesischemiainducedmicrovesselrarefactioninthemyocardiumsystemsbiologystudy
AT badimonlina allogenicadiposederivedstemcelltherapyovercomesischemiainducedmicrovesselrarefactioninthemyocardiumsystemsbiologystudy